Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors
Study Name | |
Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors | |
ClinicalTrials.gov Identifier (if applicable) | |
https://www.clinicaltrials.gov/ct2/show/NCT02746081?term=IDH1&rank=6 | |
Study Center | |
Institution Name | |
USC Norris Comprehensive Cancer Center | |
Institution Address | |
1441 Eastlake Ave | |
City | |
Los Angeles | |
State | |
California | |
Zip Code | |
90089 | |
Phone | |
(323) 865-3967 | |
Website | |
http://www.uscnorris.com | |
Study Contacts | |
Principal Investigator | |
Heinz Josef Lenz | |
P.I. Phone | |
(323) 865-3967 | |
P.I. Email | |
lenz@usc.edu | |
Study Coordinator | |
Jubilee Acap | |
Study Coordinator Phone | |
(323) 865-3900 | |
Study Coordinator Email | |
jubilee.acap@med.usc.edu | |
OVERVIEW – in layman’s terms (150 words max) | |
An Open-label, Non-Randomized (the participants are not assigned by chance to different treatment groups), Multi-center, Phase I Study. Phase II Dose of the Orally taken Mutant IDH Inhibitor BAY 1436032. Cohorts will consist of patients representing the following IDH1-R132X-mutant intrahepatic cholangioncarcinoma, glioblastoma/ anaplastic glioma |
|
Enrollment | |
open | |
Study Start Date | |
12/01/2016 | |
Estimated Completion Date | |
01/31/2018 | |
Inclusion Criteria – Patients Must: | |
|
|
REQUIRED TESTS PRIOR TO BEGINNING STUDY TREATMENT – in layman’s terms | |
|